At public hearing, FDA officials starting with acting Commissioner Sharpless emphasized CBD is approved only as a drug and deciding on allowing its use in any other type of FDA-regulated product will be done with potential impact on drug development foremost in agency's thinking. Also apparent from questions 12-member panel of FDA officials asked was a potential regulatory pathway for clearing hemp and CBD as dietary ingredients will require resolving concerns about the substances' dose or concentration levels and establishing ingredient identity standards.
US Food and Drug Administration officials are making clear that their consideration of cannabidiol's use as a dietary ingredient will prioritize weighing the potential impact of slowing or interrupting the development of drugs using cannabis-derived substances.
At a May 31 public hearing, officials starting with acting Commissioner Norman "Ned" Sharpless emphasized that CBD is approved only...